Patent ID: 9599624
Date: 2017-03-21
CPC Classifications: A61P,C07K,C12N,C12Q,C12Y,G01N

Claim:
1. A method for detecting the presence of a BARD1 isoform specific to lung cancer and colorectal cancer, the method comprising the steps of: obtaining a biological sample from a subject; providing at least one polynucleotide primer or probe, wherein said polynucleotide primer or probe is specific for an mRNA that encodes the BARD1 isoform π consisting of SEQ ID NO:1 or a sequence having at least 99% homology to SEQ ID NO:1 and for an mRNA that encodes BARD1 isoform π′ consisting of SEQ ID NO: 105 or a sequence having at least 99% homology to SEQ ID NO:105, wherein said BARD1 isoform π consisting of SEQ ID NO:1, said sequence having at least 99% homology to SEQ ID NO:1, said BARD1 isoform π′ consisting of SEQ ID NO:105, and said sequence having at least 99% homology to SEQ ID NO:105 comprise a deletion within exon 4 of said BARD1 isoform, and wherein said primer or probe specifically binds to said mRNA at the deletion junction of said deletion within exon 4; and detecting in said sample the mRNA encoding said sequence by detecting specific binding of said polynucleotide primer or probe to said mRNA, thereby detecting the presence of said BARD1 isoform specific to lung cancer and colorectal cancer, wherein the presence of said BARD1 isoform π or isoform π′ specific to lung cancer and colorectal cancer in a sample from said subject is an indication that said subject is afflicted with lung cancer and/or colorectal cancer, has an increased risk of lung cancer and/or colorectal cancer, a risk of recurrence after a treatment for lung cancer and/or colorectal cancer, and/or is an indication of reduced survival of a patient afflicted with lung cancer.